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Objectives: To elucidate the possible ways by which hydroxyurea molecules affect globin chain (α 
or β-like) synthesis.
Methods: A total of 23 thalassemia intermedia patients (13 male and 10 female) aged between 
5 and 26 years were treated for five months with 15 mg/(kg·day) of hydroxyurea. Hemoglobins 
electrophoresis and globin chain electrophoresis was performed on each sample at different time 
points before and during the treatment.
Results: Fetal hemoglobin increased significantly in most patients and average episodes 
of transfusion decreased. Both Gγ and Aγ-globin chains increased significantly and 
α-globin:Nonα-globin chain as well as Gγ-globin:Aγ globin chains ratios decreased.
Conclusions: Improvement in α:non-α ratio and consequent decrease of free α-globin chain 
might be the cause of beneficial effects of hydroxyurea therapy. Two patients who felt better 
didn’t show significant increase in their fetal hemoglobin level, and this is in contradiction 
with the hypothesis claiming that the HbF level increase is the cause of such therapeutic effect. 
In spite of the unclear mechanism of action of this drug, hydroxyurea therapy had noticeable 
impacts on thalassemia intermedia and also sickle cell disease and even patients suffering from 
thalassemia major.
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1. Introduction
   Hemoglobin (Hb) is the iron-containing metalloprotein 
in the red blood cells (RBCs) of all vertebrates. It is 
responsible for delivering oxygen to tissues and in human, 
it has many variants. In a normal subject, according to 
the stage of development such as embryonic, fetal and 
adult, hemoglobins are present. Hemoglobin’s quaternary 
structure comes from a roughly tetrahedral arrangement of 
its four subunits. The most common hemoglobin type is a 
tetramer consisting of two α-like (ζ or α) and two non-α-
like globin chain (ε,Gγ,Aγ,δ or β) subunits non-covalently 
bounded, each made of 141 and 146 amino acid residues, 
respectively. Globin gene activation is coordinated during 
development. The composition of the four globin chains 
determines the hemoglobin type. For example: HbA (α2β2), 
HbA2 (α2δ2),  fetal hemoglobin (HbF) (α2γ2) mutations in the 
globin genes cause hemoglobinopathies that are inherited 
diseases[1]. 
   Thalassemia has an autosomal recessive pattern of 
inheritance and is a hemoglobinopathy along with hemolytic 
anemia which is determined by hypochromic, microcytic 
and decreased RBCs lifetime caused by reduced or absence 
of one or more globin chain synthesis. The fundamental 
abnormality in thalassemia is impaired production resulting 
in an imbalanced ratio of either α or non-α globin chains. 
According to the chain involved, the two major thalassemia 
categories are α-thalassemia (reduced α globin chain 
synthesis) and β-thalassemia (reduced beta globin chain 
synthesis). 
  β-thalassemia intermedia (TI), the milder form of 
disease is a term used to define a group of patients with 
β-thalassemia, in whom the clinical severity of the disease 
is ranging between the mild symptoms of the β-thalassemia 
trait and the severe manifestations of β-thalassemia 
major. Clinical diagnosis of this disease is based on the 
hemoglobin concentration 6-7 g/dL at the time of diagnosis 
and in many cases regular blood transfusions are not 
necessary[2]. Despite tremendous advances in diagnosis 
of the genetic and molecular basis of this syndrome in the 
past decade, the diagnosis and classification of diseases is 
still largely dependent on clinical syndromes. In practical 
terms, a child who is referred to the clinic at the first time 
with hemoglobin levels less than 7 g/dL at the age of two or 
more years, with or without splenomegaly, is categorized as 
thalassemia intermedia[3].
   New estimations suggest 300 000 annual births of 
hemoglobinopathies, among which sickle cell disease (SCD) 
and the thalassemia represent the majority of cases[4,5]. In 
Iran with an approximately 15 000 thalassemic patients[1,6]; 
the most common single gene disorder is β-thalassemia. In 
north of Iran, near the Caspian sea, and south close to the 
Persian Gulf the prevalence of β-thalassemia is about 10% 
and in other parts of the country about 4%-8% prevalence 
is expected[6,7]. Patients with β-thalassemia who have 
high levels of HbF, especially patients suffering hereditary 
persistence of fetal hemoglobin, have fewer problems to 
the extent that they may be transfusion independent and 
they may live almost normally[8-10]. Three classes of HbF-
inducing agents have been investigated[11] for the treatment 
of β-thalassemia including chemotherapeutics [for example: 
hydroxyurea (HU)[12-15], 5-azacytidine[13,14], decitabine[16], 
vinblastin[17],  thalidomide[18]], pervanadate compounds[19], 
short-chain fatty acid derivatives (for example: sodium 
phenylbutyrate, arginine butyrate, hydroxycarbamide[20] 
and Isobutyramide sodium 2,2- dimethylbutyrate[16,18], 
recombinant human erythropoietin[16,21]), and recently some 
inducers from the natural world (for example: angelicin and 
linear psoralens, resveratrol, rapamycin[22] have also been 
reported to be efficient in increasing HbF levels[23]). New 
oral agents that stimulate both fetal globin gene expression 
and erythropoiesis are also promising candidates for HbF 
induction[21]. 
   HU was shown to reduce the rate of painful crises in 
adult patients who have at least three painful crises 
per year and have possible beneficial effects on HbF 
concentration increase in patients with SCD. In spite of the 
controversy over the exact mechanism of induction of HbF 
by 5-azacytidine and HU, considerable progress has been 
made in the development of these agents as drugs can 
induce HbF in patients with hemoglobin disorders[16].
   The aim of this study was to elucidate the possible ways 
by which HU molecules affect globin gene expression 
and which of the globin chains α or β-like is augmented 
in the presence of this drug. The determination of the 
location and the mechanism of action of this medication 
and similar drugs will determine the study direction of 
more efficient drugs or a multi-drug combination. There 
are only a few studies on the effect of this medication on 
α:non-α and Gγ:Aγ ratio[24]. Thus, analyzing these indices 
in TI patients seemed necessary in order to better elucidate 
the mechanism of action of HU on β globin gene cluster 
expression.
2. Materials and methods
2.1. Patients 
   This cross sectional clinical trial study, the same as a 
lot of other similar studies, has experienced the problems 
that led to restrictions on the sample size such as: medical 
ethics, patient consent, having inclusion criteria and lack 
of exclusion criteria. Inclusion criteria can be described 
as: 1) A person who suffers thalassemia intermedia; 2) 
Not suffering from another disease same as viral disease 
and don’t need drug therapy; 3) Don’t take interferon; 4) 
Has the ability to see the doctor several times; 5) With the 
doctor’s diagnose, be able for sampling and HU therapy. 
And exclusion criteria was: 1) Decreasing a large number 
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of platelets (thrombocytopenia); 2) Significant decrease in 
WBCs (leukocytopenia); 3) Dissatisfaction of patient or his 
family.
   A total of 26 thalassemia intermedia subjects aged 
between 5 and 26 years attending thalassemia department 
of the Imam Reza hospital on the north of Iran were 
initially included in this study. The average starting age of 
transfusion was 3.3 years. None of them had viral disease 
nor needed drug therapy or took interferon. All patients or 
their parents consented to participate to this study. Three 
of them were excluded from the study after the first month 
of treatment due to thrombocytopenia and consequently 
the number of cases became 23 (13 male and 10 female). All 
remaining patients were treated for five months with 15 mg/
(kg·day) of HU. About 6 mL blood was withdrawn from each 
patient before, and 2.5 months and 5 months after starting 
the HU therapy. About 14 patients were spelenectomized 
prior to this study.
2.2. Cellular and biochemical analyses
   
   Complete blood count (CBC), reticulocyte count, HbF 
concentration measurement, hemoglobins electrophoresis, 
acid acetic-urea-triton X100- poly acrylamide gel 
electrophoresis (AUT-PAGE) was performed on each sample. 
CBC was done by automated hematology analyzer Sysmex 
K-1000 Howell Jully body instrument (Sysmex, USA). 
Packed cells were prepared from blood samples collected 
in EDTA, by using isotonic normal saline (0.9%) and were 
used for estimating Hb amount by means of acetate 
cellulose according to the separation instruction from 
Helena company. After electrophoresis, plates were stained 
using ponceau S and destained three times with 5% acetic 
acid solution. Then, dehydration was done in the presence 
of absolute methanol, and finally the slides were cleared 
by means of clear aid followed by heating at 80 °C in the 
oven. The slides were scanned with a densitometer at 540 
nm wavelength and the acquired curves were analyzed by 
appropriate software. In this method (pH=8.6) the movement 
of Hemoglobins from negative to positive (cathode to anode) 
are HbA, HbF and HbA2 respectively.
   HbF was measured by resistance to alkali denaturation 
method of Singer[25]. Pure water (hypotonic solution) was 
used for RBCs lysis, then the solution was saturated by 
mean of ammonium sulphate and the pH was changed 
by using NaOH. All Hbs except HbF, salted out. Optical 
density of filtered solution containing HbF was measured 
at 540 nm. Globin chains were separated by AUT-PAGE by 
a modification of Rovera’s method which consists of a high 
decrease in electrophoresis time.
   Acrylamide gels with 0.67% bisacrylamide were prepared. 
Preelectrophoresis was performed first on acetic acid 
buffer at 200 V for 45 min and then at the presence of 
2-mercaptoethanol at 150 V for 30 min. Samples were 
prepared in acetic acid and 2-mercaptoethanol and 
electrophoresed for 4.5 h at 150 V[23]. After electrophoresis, 
the gels were stained in coomassie blue for 24 h and then 
destained for few days. All instruments were calibrated by 
standard methods.
   
2.3. Statistical analysis
   In order to statistical analysis, student’s t-test by 
SPSS software was used and the sign test were used for 
nonparametric methods[24].
3. Results
   HU therapy caused dramatic changes in the average 
episodes of transfusion from (10依7.7) per 5 months before 
treatment to (3.6依3.8) per 5 months during treatment and all 
patients were satisfied and felt better. In clinical history, 
all patients reported an increase in their ability for physical 
and intellectual activities and due to the decrease of 
transfusion, less need to desferal therapy. Table 1 shows the 
blood parameters before and during treatment at 2.5 and 5 
months. Blood cells indices not only can be a response of 
the medication efficiency, but also a symbol of patient’s 
healthcare. Variations in CBC before, 2.5 and 5 months after 
treatment are shown in Table 1.  
Table 1
Blood parameters before and during treatment at 2.5 and 5 months.
Blood indices Onset After 2.5 months After 5 months P value
WBC 499.00依17.80 566.00依20.40 747.00依35.10 >0.05
RBC   3.19依0.46  3.32依0.43  3.58依0.40 <0.05
HCT 24.99依2.52 25.86依2.26  2.83依2.48 <0.05
MCV 76.90依6.08 77.93依6.24 80.79依6.36 <0.05
MCH 23.60依1.93 24.06依2.17 25.06依2.07 <0.05
MCHC 29.56依2.44 31.10依1.65 31.62依1.74 <0.05
Platelet   520.52依214  480.57依187.00  405.22依188.00 <0.05
Retic count   8.90依3.14  6.55依3.42  4.71依2.17 <0.05
   In order to evaluate whole Hb molecules and look for Hb 
variants, the study took advantage of Hb electrophoresis 
on acetate cellulose. Figure 1 shows a slide containing 8 
samples of acetate cellulose electrophoresis, and an example 
of scanning curve may be seen in Figure 2. 
Sample Origin
HbA2, C or E
HbF
HbA1
Carbonic Anhydrase
Figure 1. A Helena acetate cellulose electrophoresis slide with 8 samples.
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Figure 2. A scanned curve of  Helena acetate cellulose electrophoresis 
slide for 1 sample.
*HEMOGLOBN*
%       Normal (%)
A1    38.7      96.6-98.5
F      60.3      0    -    2
A1    1.00      1.5 - 3.5
   Then globin chains were measured separately by AUT-
PAGE. Figure 3 represents the electrophoresis pattern. The 
bands absorbance on the gel was measured at 590 nm by 
densitometry. 
Figure 3. Tubes with poly acrylamide gels after staining and destaining. 
The increment of γ chains after 2.5 and 5 months is so clear. From the top to 
the bottom, bands correspond to carbonic anhydrase and globin chains Aγ, 
Gγ, β and α respectively.
1
2
3
Aγ
Gγ
α
β
   Figure 4 represents a density pattern obtained for one 
of the samples. Total hemoglobins, HbF, Gγ:Aγ as well 
as α:non-α chains ratio were assessed before, 2.5 and 5 
months after HU therapy. Table 2 represents those molecular 
indices. Variations of HbF as well as α/non-α chains for all 
23 patients are represented in Figure 5 and 6 respectively. 
Figure 4. A scanned graph of one sample of polyacrylamide gel 
electrophoresis.
Globin Chain        %
α     01                     50.7 
β     02                     14.2
Gy   03                     23.7
Ay   04                     11.7
Table 2
Molecular parameters before and during treatment at 2.5 and 5 months.
Parameters Onset After 2.5 months After 5- months P value
Total Hb 7.64依0.91  7.99依0.85  8.74依0.98 <0.05
HbF 6.90依4.77 11.71依5.69 15.48依6.09 <0.05
Gγ 13.19依7.67  15.20依10.42 1  6.27依10.98 <0.05
Aγ 5.78依4.46  8.49依5.28 11.52依6.45 <0.05
Gγ/Aγ 3.22依2.54  1.92依0.85   1.43依0.50 <0.05
α/non-α 1.09依0.21  0.95依0.12   0.91依0.12 <0.05
Figure 5. Varriation of HbF at onset, 2.5 and 5 months of clinical trial by 
alkali denaturation test.
Onset of Trial
Average依SD         2.96依2.05                  5.02依2.47                           6.65依2.62
12
10
8
6
4
2
0
2.5 Monthes after Treatment 5 Monthes after Treatment
   1    2      3     4    5     6       7    8     9     10   11   12   13    14    15   16    17   18   19    20    21   22   23
Patient Number
H
bF
 (g
/d
L)
Figure 6. Varriation of α/non-α chains ratio at onset, 2.5 and 5 months of 
clinical trial.
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   In patients number 9 and 18 a slight decrease in the 
whole process of treatment and in patient number 6, a slight 
decrease in the second phase followed by a slight increase 
in the 3rd phase of sampling was observed in Figure 5. In the 
other 20 patients HbF increased significantly (P<0.05). 
   According to Table 2, it seems that the amount of α chain 
decreased gradually and shifted to make a balance with 
non-α. Also the amount of β chain decreased from (29.27
依13.28) percent at the treatment onset to (24.72依17.08) at 
the end of the treatment. Therefore, the ratio of α:non-α 
decreased from (1.09依0.21) to (0.91依0.12) (Figure 6). 
   Gγ variation was discordant in this survey as it increased 
in some patients and decreased in others. But according to 
Table 2, it’s average amount increased during the treatment 
period, from (13.19依7.67) at the beginning of treatment 
to (16.27依10.98) at the end of this study, which shows a 
significant change. (P<0.05). Although Aγ showed an 
alternative increase and decrease during the study, but as 
shown in Table 2, an overall increase in the amount of Aγ 
is observed from (5.78依4.46) at the beginning of treatment to 
(11.52依6.45) at the end, which is considered as a significant 
increase(P<0.05).
   Gγ:Aγ showed a decrease in almost all patients during 
the period of drug administration (Table 2 Figure 7); because 
of an excess increase in two patients at the first stage 
of the treatment, the average of this ratio shows a slight 
increase, despite a moderate decrease in other patients. By 
discarding the data corresponding to the above cited two 
patients, an important decrease in the ratio of Gγ:Aγ from 
(2.22依2.54)% to (1.43依0.50)% at the end of the treatment period 
can be noticed.
Figure 7. Varriation of Gγ/Aγ chains ratio at onset, 2.5 and 5 months of 
clinical trial.  
12.00
10.00
8.00
6.00
4.00
2.00
0.00
2.5 Monthes after Treatment
5 Monthes after Treatment
   1      2     3      4      5    6      7     8     9      10   11    12   13    14   15    16    17    18    19    20   21    22   23
Patient Number
Ggamma/Agamma Ratio
Onset of Trial Average 依 SD
3.22依2.54
1.92依0.85
1.43依0.50
   In AUT-PAGE method for α, β, Gγ and Aγ measurement in 
three patients, A sample of three samples lost and the data 
are average of two stages sampling.
   Regression analysis of some indices is presented in 
Figure 8-12. The correlation between Gγ and HbF which is 
represented in Figure 8 shows fewer changes. As shown in 
Figure 9, the correlation between HbF and total Hb during 
the treatment is r1=0.29, r2=0.23, r3=0.25 respectively which 
shows a decrease of the correlation between these two 
indices. Although there is a direct relationship between 
total Hb and HbF increase, because of a higher increase 
of HbF in HU treated patients, the correlation between 
these two indices decreased slightly during treatment. The 
correlation between Aγ and HbF is represented in Figure 
10. The correlation between total Hb increase with α:non-α 
decrease and Gγ:Aγ ratios is represented in Figure 8 and 
10. According to Figure 11 a weak correlation exists between 
total Hb and Gγ:Aγ ratio. The comparison of Figure 11 with 
Figure 12 which represents the correlation of total HB with 
α:non-α, suggests that the correlation between these two 
latter indices (r=0.20) is more than the regression coefficient 
of total Hb with Gγ:Aγ (r=0.07).
Figure 8. Correlation between Gγ and HbF at onset, 2.5 and 5 months of 
clinical trial.
0.00              2.00              4.00              6.00               8.00             10.00             12.00           14.00
Onset of the Trial
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40.00
35.00
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10.00
5.00
0.00
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2.5 Monthes after 
Treatment
5 Monthes after 
Treatment
y(1) =2.4362x+5.6736
r =0.4036
y(2) =2.839x+1.2214
r =0.4548
y(3) =2.6455x+1.3002
r =0.4002
5 Monthes after TreatmentG
ga
m
m
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%
)
Figure 9. Correlation between HbF and total Hb at onset, 2.5 and 5 months 
of clinical trial.
HbF(g/dL)
6.00       6.50        7.00      7.50        8.00        8.50       9.00       9.50       10.00           10.50  11.00
T.Hb(g/dL)
Onset of the Trial
Onset of the Trial
12.00
10.00
8.00
6.00
4.00
2.00
0.00
2.5 Monthes after Treatment
2.5 Monthes after 
Treatment
5 Monthes after 
Treatment
y(1)= 1.2017x-6.2198
r =0.2884
y(2) =1.5465x-7.5445
r =0.2511
y(3)= 1.2943x-4.6676
r =0.2308
5 Monthes after Treatment
Figure 10. Correlation between Aγ and HbF at onset, 2.5 and 5 months of 
clinical trial. 
Agamma(%)
0.00                2.00              4.00              6.00               8.00             10.00            12.00            14.00
HbF(g/dL)
Onset of the Trial
Onset of the Trial
25.00
20.00
15.00
10.00
5.00
0.00
2.5 Monthes after Treatment
2.5 Monthes after Treatment
y(1) =1.5869x+0.8881
r =0.5032
y(2) =1.6286x+0.4763
r =0.5858
y(3) =1.6685x+0.438
r =0.4614
5 Monthes after Treatment
5 Monthes after Treatment
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Figure 11. Correlation between decrease of Gγ/Aγ and increase of T.Hb at 
onset, 2.5 and 5 months of clinical trial
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Figure 12: Correlation between decrease of α/Non-α and increase of T.Hb 
at onset, 2.5 and 5 months of clinical trial
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4. Discussion
   Many studies demonstrate an increase of HbF in 
SCD patients after HU administration[26,27]. However 
investigations on the effect of this drug on thalassemia had 
different and sometimes contradictory results, showing an 
increase of β and γ chains in some studies or little effect 
in others[28-31]. In this study some beneficial effects of HU 
administration due to an increase of the γ  globin chains 
was observed. Beneficial effects were also suggested by 
other studies on Sickle/βThal, Hb lepore/ βthal, βThal/HbE 
and other TI patients.
   The amount of WBC indices in this study during the 3 
phases of sampling showed no significant change in the 
patients (P>0.05). Although WBC is not an important criteria 
in TI therapy but because of its role in health and survival, 
it can may be considered as another exclusion criteria 
during HU therapy.
   An increase in the amount of RBCs which are the only 
carriers of hemoglobins in blood circulation and are 
considered as the most important problem in thalassemia 
patients, was observed in this study (P<0.05) which may 
have caused a significant decrease in the transfusion 
episodes. Contrary to some reports[32-34], in this study, 
we found a significant increase in the amount of total Hb 
(P<0.05) which is in agreement with the findings of Kosaryan 
et al[35]. An increase in vital ability, physical activities and 
a decrease of transfusion dependence and also a lower 
bone deformities in patients treated with HU can also be 
attributed to the increase of total Hb. HCT increase reflects 
RBC and MCV increase and consequently is an expected 
result. Significant increase of total Hb and HCT similar to 
those observed in our study, was also previously reported[35-
37] although Karimi et al. did not observe such changes[38]. 
   Other indices of blood cells like MCV and MCH also had 
a significant increase which is in agreement with other 
studies[39,40]. An increase in the amount of HCT, MCV and 
MCH is due to natural erythropoiesis improvement. Like the 
study of Dixit et al[41], the results of this study have shown 
a significant increase in MCHC whereas some drugs have 
shown different effects in thalassemic patients[42]. Although 
we noticed a significant decrease in the average level of 
patients platelet, but this decrial was not so important to 
necessitate a treatment arrest. A significant decrease in 
reticulocytes count level which was also reported by Dixit 
et al[41], might reflect bone marrow stress associated with 
hypoxia (anoxia) improvement, although it can also be due 
to the toxicity of the drug on bone marrow.
   However, the fact that the increase in Hb decreases the 
number of reticulocytes and supports the erythropoiesis 
improvement hypothesis. Most of the latest studies 
performed on the effect of HU on TI are in agreement with 
the results obtained from this study showing an increase in 
the level of HbF[21,43]. In fact, the first observed hematologic 
response of patients to treatment is an increase of HbF 
level. Zeng and his colleagues believed that HU was acting 
by increasing the production of β globin chain[44] but we 
observed an increase in γ chain and HbF consequently. 
Studies performed on k562 cell lines reported an increase 
in the amount of γ chains[18]. Thus, the increase in 
the production of HbF might have a relation with the 
improvement of α/non-α after HU therapy.
   In severe β-globin disorders, bone marrow failure 
resulting in aplastic crises (secondary to myelotoxicity) may 
be followed by the temporary reduction in the reticulocytes 
count, LDH, bilirubin and a temporary increase of the 
HbF level. Such effects are mostly followed by a higher 
decrease in the amount of reticulocytes counts (up to zero) 
and continuous decrease in the hemoglobin level, while 
the average level of the total red blood cells will remain 
unchanged.
   In the present study, blood globin chains were separated 
and the α:non-α and Gγ:Aγ ratio were surveyed. According 
to our results, a short decrease in the amount of α globin 
which might reflect an increase in γ chains occurred. The 
amount of β globin also decreased slightly and in a similar 
manner, this decrease might not correspond to the absolute 
amount of β chains but also reflects the increase of the total 
level of globin chains. The amount of Gγ and Aγ increased 
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dispersedly in the patients and the average level of both 
chains showed a significant increase (P<0.05). However, the 
total amount of gamma chains increase in patients is more 
important[14,45]. Zeng and his colleagues suggested that the 
increase of total Hb is due to the increase of β globin level 
not γ chain[46]. Most of the studies performed to date are in 
agreement with our results concerning the improvement 
in α:non-α ratio being the cause of beneficial effects of 
HU therapy and the decrease of free α-globin chain[47]. A 
significant decrease in the above ratio was also  reported by 
Fucharoen and his colleagues who also reported a decrease 
in  Gγ:Aγ while this  decrease was not significant[48].
   The reason of observed effects in HU therapy in TI patients 
has not been clearly demonstrated. Studies on k562 cell 
lines show that the increase of Aγ and Gγ chains at cellular 
level is in accordance with the effect of this drug at the 
genomic expression level. Researches on DNA methylation, 
showed that unlike 5-azacytidine, the mechanism of HU 
action is not related to the methylation modifications or 
-158 XmnI SNP[49] and probably mediated by additional 
mechanisms[50]. Furthermore, two patients who feel better 
did not show significant increase in their HbF level, which 
is in contradiction with the hypothesis claiming that the 
HbF level increase is the cause of such therapeutic effect. 
In spite of the unclear mechanism of action of this drug, HU 
therapy had noticeable impacts on TI and also SCD and even 
patients suffering from thalassemia major[51] and its limited 
side effects[28] make it a good candidate for these diseases 
therapy.
   The comparison of two regression analysis (Gγ and Aγ 
compared with HbF) shows that the increase in HbF level is 
more correlated with Aγ augmentation. This idea is further 
supported by the decrease of Gγ:Aγ ratio and increased 
correlation between Aγ and HbF during HU therapy as well 
as the increase of the average of the two latter indices[11]. 
Finally we deduced that the imposed effect of HU on Aγ is 
more than Gγ.
   The advantages of using this medication appears to be 
more than an increase in HbF levels, but the increase of the 
α:non-α ratio can be considered as one of the main reasons. 
Since, disproportion in α:non-α ratio have been known as 
a molecular agent of problems observed in thalassemia in 
many studies, Thus the imbalance between two groups of 
globin molecules causes accumulation of α-like globin 
chains and especially α-globin chain in patients with β 
thalassemia. This condition provides insoluble deposits 
inside the red blood cells that causes deformation, 
instability and destruction of the cell membrane (decreased 
cellular deformability). Although the increment of HbF and 
HbA2 is a pleasant event in patients with β-thalassemia 
but because of high affinity for oxygen and more stability 
of oxygen binding that mentioned for two molecules in 
comparison to HbA1, the efficiency of the HbF and HbA2 
in compared with HbA1 is reduced. Our observations of the 
23 patients indicate that satisfaction and positive changes 
created in daily life of above patients are beyond of the 
significant changes observed in HbF, γ-globin chains, 
Gγ/Aγ ratio, α:non-α ratio, retic count, etc. This results 
is confirmed based on the life quality improvement in 3 
patients that have been observed any increase in the level 
their HbF. Therefore, it appears that supplementary reasons 
should be found in association with the benefits of this drug 
in patients with thalassemia such as the enhancement in 
production nitric oxide, structural changes in the binding 
and release of oxygen from hemoglobin, improvement in 
tissues oxygen consumption, expression of some genes 
unrelated to the globin chains, change in level of some 
hormones, etc.
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Comments 
Background
   Increased level of HbF may ameliorate the clinical crisis 
of β-thalassemia and SCD. Many agents stimulate HbF 
augmentation in vivo such as 5-azacytidine, butyrate, and 
HU. The mechanisms of action of these agents are different 
and not yet understood clearly. So in order to design new 
drugs, understanding the mechanism of these drugs at the 
molecular level can be helpful to modern advances.
  
Research frontiers
   The present study demonstrates HU beneficial effects on 
the patient condition by increasing HbF. Also, α-like:β-like 
globin chain ratio, Gγ and Aγ has been studied to better 
understand the biochemical and genetic effects of HU.
Related reports
   Recent studies showed that HU and its derivatives 
can stimulate the in vivo erythropoiesis and fetal globin 
production in thalassemia patients, a substantial and 
persistent increase in total hemoglobin level and a 
significant decrease in blood transfusion. Increased 
HbF production in β-thalassemia/HbE patients, with an 
improvement in the α:non-α globin ratios and probably, 
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the effectiveness of erythropoiesis, can be achieved using 
HU.
Innovations and breakthroughs
   Although HU is prescribed to thalassemia patients as 
appropriate and FDA-approved medication, this research 
study introduced new insights in globin chain production 
and molecular mechanisms of this drug. AUT-PAGE method 
with an improvement on electrophoresis duration is another 
novelty of this research.
  
Applications
   Improvement of electrophoretic dissociation method of 
metalloproteins can be used in research and diagnostic 
laboratories and augmentation of HbF. 
Peer review
   Over all the paper is very informative and gives scientific 
information. This is an interesting study where the authors 
have studied the influence of HU on WBC, total Hb, HbF, 
globin chains synthesis and ratio, α:non-α and Gγ:Aγ. 
HU showed effective influence on clinical condition of 
thalassemia intermedia patients. This study is important 
and useful to those who work on thalassemia intermedia, 
drug inducers of HbF, electrophoresis, gene therapy etc.
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